Magnetic Nanoparticles and Quantum Dots for Diagnosis of Early Stage Ovarian Canc

磁性纳米颗粒和量子点用于诊断早期卵巢癌

• 批准号: 7910338
• 负责人: ZORAIDA Pascual AGUILAR
• 金额: $ 15.01万
• 依托单位: OCEAN NANOTECH, LLC
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-07-12 至 2012-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7910338
• 关键词: Achievement; American; Antibodies; Binding; Biological; Biological Assay; Biological Markers; Biological Process; Biopsy; Biosensor; Buffers; Build-it; CA-125 Antigen; Caliber; Cancer Patient; Cells; Clinical; Clinics and Hospitals; Color; Comparative Study; Cytochromes; Decision Making; Detection; Development; Devices; Diagnosis; Diagnostic; Diagnostic Neoplasm Staging; Diagnostic Procedure; Disease; Drug Monitoring; Early Diagnosis; Early treatment; Electrodes; Electron Transport; Engineering; Epidemiology; Epididymis; Equipment; Exhibits; Fluorescence; Fluorescent Antibody Technique; Foundations; Fred Hutchinson Cancer Research Center; G-substrate; Generations; Goals; Gold; High Risk Woman; Hour; Human; Hybrids; Image; Immobilization; Immunoassay; Immunomagnetic Separation; Individual; Label; Lead; Letters; Lighting; Liquid substance; Magnetism; Malignant Neoplasms; Malignant neoplasm of ovary; Manuals; Marketing; Mechanics; Medical; Membrane; Methods; Microfluidics; Microspheres; Modeling; Monitor; Nanotechnology; Oceans; Optics; Ovarian; Patients; Pharmaceutical Preparations; Phase; Precipitation; Preparation; Printing; Property; Protein Array; Proteins; Pump; Quantum Dots; Reading; Reagent; Reliability of Results; Reporter; Reporting; Research; Rest; Sampling; Scheme; Screening for Ovarian Cancer; Screening for cancer; Serum; Signal Transduction; Solutions; Source; Staging; Surface; Survival Rate; Symptoms; Syringes; System; Techniques; Technology; Therapeutic; Therapeutic Agents; Time; Ultrasonography; United States National Institutes of Health; Universities; Vaccines; WFDC2 gene; Washington; West Virginia; Woman; Work; austin; base; cancer diagnosis; cancer type; clinical Diagnosis; cost; density; design; drug efficacy; efficacy testing; gel electrophoresis; high throughput analysis; high throughput screening; hospital laboratories; improved; innovation; instrument; iron oxide; magnetic beads; mesothelin; micro-total analysis system; miniaturize; nano; nanocrystal; nanofabrication; nanoparticle; nanoscale; novel; preclinical study; programs; prototype; public health relevance; quantum; rapid detection; response; seal; sensor; success; tool; ultraviolet; user-friendly; vaccine development

DESCRIPTION (provided by applicant): Ocean NanoTech proposes to develop a portable, sensitive, high throughput, low cost, and user friendly system for the early stage diagnosis of ovarian cancer using magnetic nanoparticles (MNPs), quantum dots (QDs), and a nanoelectrode array (NEA) all integrated in a disposable lab-on-a-chip. The proposed system will consists of a fully automated instrument that requires a disposable lab-on-a-chip device that uses very sensitive high quantum yield quantum dots and nanoelectrode array for signal generation in the diagnosis of stage I levels of ovarian cancer biomarkers at concentrations potentially d 1 ng/mL in a d 60 min assay. It will be fully automated allowing high throughput analysis, high sensitivity with > 95% reliability, and minimizing false positives and false negatives. Unlike existing diagnostic methods of ovarian cancer which are either invasive or detect biomarkers too late in the progress of the disease leading to very low survival rate, the proposed system is anticipated to detect early stages of the disease which is the most promising approach to the long term survival of ovarian cancer patients. The proposed system is anticipated to diagnose early stage ovarian cancer that can be used for the following very important purposes: 1) regular monitoring of high risk women; 2) diagnose early stage of the disease at the onset of vague clinical symptoms; 3) monitor changes in the ovarian cancer biomarker levels during medication; and 4) detection system during the development and efficacy testing of drugs, vaccine, or other therapeutic molecules. PUBLIC HEALTH RELEVANCE: Our goal is to develop a portable, sensitive, high throughput, low cost, and user friendly system for the early stage diagnosis of ovarian cancer that uses a disposable lab-on-a-chip that integrates the advantages of magnetic nanoparticles (MNPs), quantum dots (QDs), and nanoelectrode array (NEA) for fluorescence as well as nanoelectrochemical detection. We will develop the best combination of MNPs, QDs, and NEA for isolation and detection of multiple ovarian cancer biomarkers for early diagnosis and possible early treatment of approximately 20,000 American women who are diagnosed with ovarian cancer and of whom 15,000 die each year.

描述（由申请人提供）：海洋纳米技术建议使用磁性纳米颗粒（MNP）（MNP），量子点（QDS）和纳米电极阵列（NEA）开发出一种便携式，敏感，高吞吐量，低成本和用户友好的系统，用于对卵巢癌的早期诊断，所有这些都集成在dopososeable Labable Labable Lab-an-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-con-chip中。所提出的系统将由一种全自动的仪器组成，该仪器需要使用一次性实验室芯片设备，该器件使用非常敏感的高量子产量量子点和纳米电极阵列，以诊断为I型卵巢癌生物标志物在D 60分钟内的卵巢癌生物标志物的诊断，浓度为D 1 ng/mL。它将是完全自动化的，允许高吞吐量分析，> 95％的可靠性以及最小化假阳性和假否定性的高灵敏度。与现有的卵巢癌诊断方法不同，卵巢癌在疾病的进展中为时已晚，导致生存率非常低，预计该疾病的生存率很低，预计该疾病的早期阶段是对卵巢癌患者长期生存的最有希望的方法。预计拟议的系统将诊断出可用于以下非常重要目的的早期卵巢癌：1）定期监测高风险女性； 2）在模糊的临床症状发作时诊断疾病的早期阶段； 3）监测药物治疗过程中卵巢癌生物标志物水平的变化； 4）在药物，疫苗或其他治疗分子的开发和疗效测试期间的检测系统。 PUBLIC HEALTH RELEVANCE: Our goal is to develop a portable, sensitive, high throughput, low cost, and user friendly system for the early stage diagnosis of ovarian cancer that uses a disposable lab-on-a-chip that integrates the advantages of magnetic nanoparticles (MNPs), quantum dots (QDs), and nanoelectrode array (NEA) for fluorescence as well as nanoelectrochemical detection.我们将开发MNP，QD和NEA的最佳组合，用于隔离和检测多种卵巢癌生物标志物，以早期诊断，并可能早期治疗约20,000名被诊断出患有卵巢癌的美国女性，每年15,000例死亡。